Kaneka Corporation has announced the signing of a sales alliance agreement with Asahi Intecc USA, through which—from August 2021 onwards—the company intends to further expand its sales in the US market.
This follows Kaneka gaining US Food and Drug Administration (FDA) approval for its latest brain aneurysm embolisation coil, the i-ED coil, in April 2020. The company has also been marketing this device through Kaneka Medical America since September 2020.
The i-ED coil—a new product with the “best-in-class level of coil flexibility”, according to Kaneka—was launched on the Japanese market in November 2019. Sales of the device have been “steadily increasing” as the product has been “praised highly” by Japanese neurosurgeons for its ability to reduce aneurysm rupture risks, as per a Kaneka press release.
In addition, Kaneka Medical America has been promoting the product at major stroke centres in the USA, and will accelerate penetration of the i-ED coil in the US market in close collaboration with Asahi Intecc USA, which has its own sales network in the same field.